SpringWorks Therapeutics ...

NASDAQ: SWTX · Real-Time Price · USD
46.99
0.00 (0.00%)
At close: Jun 30, 2025, 3:59 PM

SpringWorks Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
219.67M 191.59M 135.49M 91.77M 37.87M 22.42M 22.77M 18.02M 12.54M 6.99M 1.19M 474K 296K 521K 35.52M 35.4M 35.23M
Cost of Revenue
14.88M 13.28M 8.69M 6.28M 4.66M 3.27M 2.85M 2.41M 2.06M 1.9M 1.5M 1.36M 1.25M 1.24M 1.09M 727K 367K
Gross Profit
204.79M 178.31M 126.8M 85.5M 33.21M 19.15M 19.92M 15.61M 10.49M 5.09M -310K -891K -952K -714K 34.43M 34.67M 34.86M
Operating Income
-264.74M -278.13M -295.25M -321.31M -359.25M -343.01M -323M -310.75M -296.9M -280.67M -258.02M -227.17M -205.18M -173.47M -106.45M -87.15M -59.95M
Interest Income
18.43M 26M 26.17M 25.61M 24.66M 22.65M 21.85M 17.1M 11.64M 6.29M 1.56M 830K 669K 698K 791K 675K 621K
Pretax Income
-253.93M -258.13M -275.16M -301.06M -339.07M -325.1M -304.96M -297.91M -289.04M -277.42M -259.31M -227.96M -205.92M -173.91M -106.57M -87.18M -60.07M
Net Income
-253.93M -258.13M -275.16M -301.06M -339.07M -320.82M -296.4M -288.44M -279.57M -272.23M -258.4M -227.96M -205.92M -173.91M -106.57M -87.18M -60.07M
Selling & General & Admin
273.04M 255.92M 238.66M 223.6M 212.76M 197.55M 178.24M 167.37M 151.36M 134.55M 120.48M 102.83M 86.78M 71.79M 53.86M 43.5M 35.44M
Research & Development
196.49M 200.52M 183.93M 179.09M 170.59M 150.49M 144.76M 143.38M 145.54M 146.12M 137.54M 124.34M 118.4M 101.68M 87.59M 78.65M 59.51M
Other Expenses
n/a n/a 373K 297K 199K n/a -220K -218K -144K -138K -347K -331K -348K -152K -96K -38K 3K
Operating Expenses
469.53M 456.44M 422.59M 402.69M 383.35M 348.04M 323M 310.75M 296.9M 280.67M 258.02M 227.17M 205.18M 173.47M 141.45M 122.15M 94.95M
Interest Expense
-998K n/a 4.28M 4.28M 4.28M 4.28M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a -729K -729K -729K -729K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
484.41M 469.72M 430.74M 407.5M 385.7M 348.46M 323M 310.75M 296.9M 280.67M 258.02M 227.17M 205.18M 173.47M 141.45M 122.15M 94.95M
Income Tax Expense
n/a 685.72K 685.72K 685.72K 303.72K -4.66M -8.94M -9.85M -9.84M -5.76M -1.56M -830K -669K -698K -617K -501K -447K
Shares Outstanding (Basic)
74.89M 74.13M 74.26M 74.12M 73.77M 73.49M 62.52M 62.46M 62.33M 62.42M 52.9M 49.07M 48.94M 48.74M 48.6M 48.42M 48.23M
Shares Outstanding (Diluted)
74.89M 74.13M 74.26M 74.12M 73.77M 73.49M 62.52M 62.46M 62.33M 62.42M 52.9M 49.07M 48.94M 48.74M 48.6M 48.42M 48.23M
EPS (Basic)
-3.41 -3.48 -3.72 -4.27 -4.98 -4.91 -4.75 -4.83 -4.99 -5.14 -5.17 -4.66 -4.22 -3.58 -2.13 -1.8 -1.3
EPS (Diluted)
-3.41 -3.48 -3.72 -4.27 -4.98 -4.91 -4.75 -4.83 -4.99 -5.14 -5.17 -4.66 -4.22 -3.58 -2.13 -1.8 -1.3
EBITDA
-262M -274.66M -292.26M -318.71M -357.1M -341.35M -321.62M -309.64M -295.99M -279.91M -257.36M -226.61M -204.69M -172.98M -106M -86.72M -59.56M
EBIT
-180.16M -274.09M -295.25M -321.31M -359.25M -343.01M -323M -310.75M -296.9M -280.67M -258.02M -227.17M -205.18M -173.47M -106.4M -87.1M -59.9M
Depreciation & Amortization
2.74M 3.47M 2.99M 3.04M 3.03M 2.84M 2.85M 2.41M 2.06M 1.9M 1.5M 1.36M 1.25M 1.24M 1.2M 932K 646K